Dexelvucitabine (Reverset; d-d4FC), a Cytidine analog, is an orally active nucleoside reverse transcriptase inhibitor. Dexelvucitabine is a powerful agent against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2′-Deoxycytidine antiretroviral agent In Vivo Dexelvucitabine (Reverset; d-d4FC; 33.3 mg/kg by i.v. or p.o.) has distribution and elimination half-lives (t 1/2α and t 1/2β , respectively) of 0.7 and 3.6 h in monkeys, respectively. The C max ranges from 21.1 to 47.5 μM. Dexelvucitabine has a favorable pharmacokinetic profile with a long half-life (4.71 and 10.75 h after administration by the intravenous [i.v.] and oral [p.o.] routes, respectively) in woodchucks. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:HIV-1